Primary Hyperoxaluria Type 3
5 clinical trials · Condition
◉ Watch Primary Hyperoxaluria Type 3
| Record | Firm | Date |
|---|---|---|
| Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3 (NCT06465472) | Biocodex | 2024-08-01 |
| Nedosiran in Pediatric Patients From Birth to 11 Years of Age With PH and Relatively Intact Renal Function (NCT05001269) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2022-02-22 |
| Natural History of Patients With PH3 and a History of Stone Events (NCT04542590) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2021-09-09 |
| Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients (NCT04555486) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2020-09-14 |
| Early Check: Expanded Screening in Newborns (NCT03655223) | RTI International | 2018-10-15 |
Track Primary Hyperoxaluria Type 3 automatically
Every clearance here is in the API, with alerts when new ones post.